Table 4.
Patients with testicular germ cell tumors who underwent cisplatin-based chemotherapy and experienced a thromboembolic event in the literature
|
Ref.
|
Number of patients
|
Percentage of patients with TE
|
Main findings
|
| Piketty et al[9], 2005 | 100 patients with GCT; 100 controls with various neoplasms | 19 (19%) | > All stages of TGCT; |
| > TE: 1st day of chemo to 6 mo after; | |||
| > Of 19 TEE, 14 occurred during chemotherapy, 5 after chemo; | |||
| > Risk factors for TEE: High body surface area, elevated serum LDH | |||
| Honecker et al[6], 2013 | 193 | 22 (11%) | > All stages of TGCT; |
| > TEE: Considered therapy-associated if occurred from start of chemotherapy to 6 wk after; | |||
| > 18 (%) TEE occurred before chemotherapy; | |||
| > Risk factors for TEE: Pure seminoma, retroperitoneal or supraclavicular lymph node metastases, elevated LDH, CVC | |||
| Bezan et al[18], 2017 | 657 | 34 (5.2%) | > All stages of TGCT; |
| > TEE: During 1st year of follow-up; | |||
| > Risk factors for TEE: Higher clinical stage and RPLN, increased number of cycles of chemotherapy | |||
| Tran et al[19], 2019 | 1135 | 150 (10%) | > Metastatic TGCT; |
| > TEE: During or within 90 d of chemotherapy; | |||
| > Risk factors for TEE: Large RPLN, CVC | |||
| Paffenholz et al[16], 2019 | 225 | 49 (19%) | > All stages of TGCT; |
| > TEE: Start of chemotherapy to 6 mo after; | |||
| > Risk factors for TEE: Higher clinical stage, elevated serum LDH, febrile neutropenia, CVC; | |||
| > Patients with TEE had significantly reduced overall survival during median follow-up of 8 mo | |||
| Current Study, 2020 | 68 | 18 (26.5%) | > All stages of TCGT; |
| > TEE: Following orchiectomy; | |||
| > Risk factors for TEE: Higher pathologic stage, greater number of chemotherapy cycles |
TGCT: Testicular germ cell tumor; TEE: Thromboembolic event; LDH: Lactic acid dehydrogenase; RPLN: Retroperitoneal lymph node; CVC: Central venous catheter.